Formulatrix Announces Licensing Agreement
News Nov 02, 2005
Formulatrix has announced that it has entered into a global licensing agreement with the research division of Novartis for Formulatrix' Rock Maker software.
Rock Maker will integrate Novartis' entire crystallization process including experimental design, liquid handling, imaging, and data management.
Jeremy Stevenson, President of Formulatrix stated, "This deal reinforces our belief that Rock Maker is the premier software solution for automating protein crystallization. This sale also provides us with additional resources to invest into the continued development of Rock Maker."
Formulatrix specializes in providing technology that automates the protein crystallization process, a key part of structure based drug discovery. visit
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018